Characterization of apolipoprotein plasma triacylglycerol regulation

被引:38
作者
Wong, Kasuen
Ryan, Robert O.
机构
[1] Childrens Hosp, Oakland Res Inst, Ctr Prevent Obes Diabet & Cardiovasc Dis, Oakland, CA 94609 USA
[2] Univ Calif Berkeley, Dept Nutr Sci & Toxicol, Berkeley, CA 94720 USA
关键词
apolipoprotein A-V; lipoprotein lipase; metabolism; structure; -function; triacylglycerol;
D O I
10.1097/MOL.0b013e328133856c
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Purpose of review Cardiovascular disease is the leading cause of death in the USA, and hypertriglyceridemia represents an independent risk factor contributing to its premature onset. Apolipoprotein (apo)A-V has been shown to be a potent regulator of plasma triacylglycerol. We highlight structural aspects of apoA-V and discuss recent findings that provide mechanistic insight into its function as a regulator of plasma triacylglycerol metabolism. Recent findings Recent findings indicate that apoA-V is comprised of two independently folded domains. Fluorescence spectroscopy and truncation analysis revealed that the carboxyl-terminal region functions in apoA-V lipid binding, consistent with its known association with plasma lipoproteins. An indirect triacylglyceroi-modulating effect of apoA-V has been attributed to heparan sulfate proteoglycan binding, as confirmed by structural studies. Furthermore, apoA-V has been shown to interact with cell surface receptors, potentially facilitating lipoprotein particle endocytosis. Summary Several features of apoA-V, including extremely low plasma concentration, lack of correlation with plasma cholesterol levels despite its association with HDL, and insolubility at neutral pH in the absence of lipid, are unlike those of other exchangeable apolipoproteins. Current and future studies of apoA-V will help to shed light on the molecular basis whereby this protein functions to modulate plasma lipid homeostasis.
引用
收藏
页码:319 / 324
页数:6
相关论文
共 40 条
[21]   Differences in stability among the human apolipoprotein E isoforms determined by the amino-terminal domain [J].
Morrow, JA ;
Segall, ML ;
Lund-Katz, S ;
Phillips, MC ;
Knapp, M ;
Rupp, B ;
Weisgraber, KH .
BIOCHEMISTRY, 2000, 39 (38) :11657-11666
[22]   Apolipoprotein A-V interaction with members of the low density lipoprotein receptor gene family [J].
Nilsson, Stefan K. ;
Lookene, Aivar ;
Beckstead, Jennifer A. ;
Gliemann, Jorgen ;
Ryan, Robert O. ;
Olivecrona, Gunilla .
BIOCHEMISTRY, 2007, 46 (12) :3896-3904
[23]   The novel apolipoprotein A5 is present in human serum, is associated with VLDL, HDL, and chylomicrons, and circulates at very low concentrations compared with other apolipoproteins [J].
O'Brien, PJ ;
Alborn, WE ;
Sloan, JH ;
Ulmer, M ;
Boodhoo, A ;
Knierman, MD ;
Schultze, AE ;
Konrad, RJ .
CLINICAL CHEMISTRY, 2005, 51 (02) :351-359
[24]   Inherited apolipoprotein A-V deficiency in severe hypertriglyceridemia [J].
Oliva, CP ;
Pisciotta, L ;
Volti, GL ;
Sambataro, MP ;
Cantafora, A ;
Bellocchio, A ;
Catapano, A ;
Tarugi, P ;
Bertolini, S ;
Calandra, S .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2005, 25 (02) :411-417
[25]   Apolipoprotein A5, a newly identified gene that affects plasma triglyceride levels in humans and mice [J].
Pennacchio, LA ;
Rubin, EM .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2003, 23 (04) :529-534
[26]   Two independent apolipoprotein A5 haplotypes influence human plasma triglyceride levels [J].
Pennacchio, LA ;
Olivier, M ;
Hubacek, JA ;
Krauss, RM ;
Rubin, EM ;
Cohen, JC .
HUMAN MOLECULAR GENETICS, 2002, 11 (24) :3031-3038
[27]   An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing [J].
Pennacchio, LA ;
Olivier, M ;
Hubacek, JA ;
Cohen, JC ;
Cox, DR ;
Fruchart, JC ;
Krauss, RM ;
Rubin, EM .
SCIENCE, 2001, 294 (5540) :169-173
[28]   Postprandial increase of plasma apoAV concentrations in Type 2 diabetic patients [J].
Pruneta-Deloche, V ;
Ponsin, G ;
Groisne, L ;
Fruchart-Najib, J ;
Lagarde, M ;
Moulin, P .
ATHEROSCLEROSIS, 2005, 181 (02) :403-405
[29]   Contributions of domain structure and lipid interaction to the functionality of exchangeable human apolipoproteins [J].
Saito, H ;
Lund-Katz, S ;
Phillips, MC .
PROGRESS IN LIPID RESEARCH, 2004, 43 (04) :350-380
[30]   ApoAV reduces plasma triglycerides by inhibiting very low density lipoprotein-triglyceride (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis [J].
Schaap, FG ;
Rensen, PCN ;
Voshol, PJ ;
Vrins, C ;
van der Vliet, HN ;
Chamuleau, RAFM ;
Havekes, LM ;
Groen, AK ;
van Dijk, KW .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (27) :27941-27947